Palisade Bio, Inc. (PALI)
NASDAQ: PALI · Real-Time Price · USD
1.940
+0.100 (5.43%)
Jun 23, 2026, 4:00 PM EDT - Market closed
Palisade Bio Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
14
Market Cap
336.74M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 250.00K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Fennec Pharmaceuticals | 51.00M |
| OmniAb | 28.94M |
| Lineage Cell Therapeutics | 14.78M |
| Abeona Therapeutics | 14.54M |
| Opus Genetics | 11.98M |
| Upstream Bio | 3.32M |
| SAB Biotherapeutics | 114.70K |
| Inhibikase Therapeutics | 1.00 |
PALI News
- 12 days ago - Palisade Bio Welcomes Biopharmaceutical Industry Veterans Robert Baltera and Jordan Zwick to its Board of Directors - GlobeNewsWire
- 14 days ago - Palisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn's Disease at New York Academy of Sciences Symposium - GlobeNewsWire
- 19 days ago - Palisade Bio Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 19 days ago - Palisade Bio Slides: Corporate presentation - Filings
- 27 days ago - Palisade Bio to Participate in the Jefferies Global Healthcare Conference - GlobeNewsWire
- 5 weeks ago - Palisade Bio Slides: Corporate presentation - Filings
- 6 weeks ago - Palisade Bio files $300M mixed securities shelf - TheFly
- 6 weeks ago - Palisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108 - GlobeNewsWire